Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU StudyReportar como inadecuado




Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Advances in Therapy

, Volume 34, Issue 3, pp 686–702

First Online: 31 January 2017Received: 04 November 2016DOI: 10.1007-s12325-017-0477-z

Cite this article as: Takeuchi, T., Nakajima, R., Komatsu, S. et al. Adv Ther 2017 34: 686. doi:10.1007-s12325-017-0477-z

Abstract

IntroductionThe Adalimumab Non-interventional Trial for Up-verified Effects and Utility ANOUVEAU was a large-scale, multicenter, prospective, observational, single-cohort study that evaluated the effects of adalimumab ADA on rheumatoid arthritis RA-related work productivity and activity impairment RA-related WPAI and disease activity in routine rheumatology care in Japan.

MethodsPatients with RA were categorized as paid workers PWs, ≥35 h-week, part-time workers PTWs, <35 h-week, or homemakers HMs, unemployed and were administered the WPAI for RA WPAI-RA questionnaire. All patients who received ADA were followed for 48 weeks to evaluate safety and effectiveness.

ResultsOf the 1808 patients analyzed, 825, 243, and 740 patients were PWs, PTWs, and HMs, respectively. WPAI-RA domain scores significantly improved at weeks 12, 24, and 48 in all groups, with maximum improvement observed for PWs p < 0.05. Additionally, remission rates according to Disease Activity Score 28, erythrocyte sedimentation rate, Simplified Disease Activity Index, or Health Assessment Questionnaire-Disability Index scores and EuroQol 5-Dimension 3-Level scores significantly increased from baseline to 48 weeks in all groups p < 0.0001. Analysis of patient subgroups revealed better WPAI-RA outcomes for patients who were biologic-naïve, treated with concomitant methotrexate, or with RA duration of ≤2 years p < 0.05. The rate of serious adverse events over 48 weeks of ADA treatment was 5.23%.

ConclusionsTreatment with ADA provided sustained improvement in WPAI and had an acceptable safety profile in patients with RA.

FundingAbbVie GK and Eisai Co., Ltd.

Trial RegistrationClinicalTrials.gov identifier, NCT01346488.

KeywordsPatient safety Post-marketing surveillance study Rheumatoid arthritis TNF inhibitor Work productivity and activity impairment Enhanced contentTo view enhanced content for this article go to http:-www.medengine.com-Redeem-3D77F0604E017A74.

Download fulltext PDF



Autor: Tsutomu Takeuchi - Ryo Nakajima - Shuichi Komatsu - Kiyotaka Yamazaki - Tomohiro Nakamura - Naoki Agata - Ataru Igarashi -

Fuente: https://link.springer.com/



DESCARGAR PDF




Documentos relacionados